Synexus, one of the world’s largest clinical trials companies, has completed a secondary buyout for £83m.
Synexus supports pharmaceutical R&D through phase II, III & IV clinical trials for companies including AstraZeneca, Glaxo SmithKline and Pfizer.
“Christophe and the management team have done a fantastic job in building an international network and one of the top global players in this nascent industry in recent years and we are eager to further support the ongoing growth and help the business to break into new markets via both greenfield site openings and potential acquisition opportunities in the US, South America and Asia."
Enjoyed this? Read more from Lancashire Business View